All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Newave Pharmaceutical LLC. and Guangzhou Lupeng Pharmaceutical Co., Ltd. have identified isoquinolines acting as epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune disease.